Pancreatic Ductal Adenocarcinoma — Trials

Pancreatic Ductal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 208
Recruiting: 129
Ph III recruiting: 13
Growth YoY: +56.5%
Industry share: 50%
Top sponsor: Revolution Medicines, Inc.
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 151–172 of 172 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02959164	Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma	completed	Phase 1	36	Mohammed MilhemOTHER	1	Jul 28, 2023	clinicaltrials
NCT04990037	A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma(CAPAFOUR)	completed	Phase 1	25	Cantargia ABINDUSTRY	2	Jun 29, 2023	clinicaltrials